Resistin, a Multipotential Therapeutic Target

Being overweight and obese are risk factors that have increased during the COVID-19 pandemic; these factors increase the white adipose tissue (WAT) that increases the release of adipokines (adiponectin, leptin, and resistin). So, obesity provokes the expansion of adipose tissue; it induces changes in their macrophages of pro-inflammatory cytokines (M2 to M1). These changes increase the resistin levels with effects on the metabolism, inflammation process, glucose homeostasis, and insulin resistance, promote cell proliferation and migration, and even serve as a biomarker for tumorigenesis. Therefore, resistin is proposed as a multipotential therapeutic target to treat different diseases, between chronic-degenerative and some types of cancer, because resistin has characteristics that give it a high probability to be a therapeutic target to attend to and prevent various diseases. In different ways, developing new drugs by molecular docking to use molecules with pharmacological characteristics capable of interacting in the regions of resistin to hinder/block the interaction between resistin and their receptors (Δ-DCN, TLR4, and CAP-1) and by promoting health to reduce overweight and obesity, and this could generate lower plasma serum resistin values, so this review remarks the potential of resistin as multipotential therapeutic target.